Friday, January 30, 2015
FAIRFIELD-SUISUN, CALIFORNIA
99 CENTS

Merck to pay $3.85B for hepatitis C drug developer

Merck

FILE - This Thursday, Feb. 28, 2013 file photo shows a patch with the Merck logo on a scientist's lab coat in West Point, Pa. Merck on Monday, June 9, 2014 announced it will spend nearly $4 billion for Idenix Pharmaceuticals with a per-share bid that more than triples the hepatitis C drug developer’s latest closing price. (AP Photo/Matt Rourke, File)

By
June 10, 2014 |

TRENTON, N.J. — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck’s experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

The price for the deal announced Monday — a per-share bid more than triple Friday’s closing price for Cambridge, Massachusetts-based Idenix — seems high. However, the latest hepatitis C medicines command very high prices, the number of patients keeps rising and Merck was bidding against rivals.

Hepatitis C has become one of the hottest categories in drug research as companies race to develop a combination therapy without injections and debilitating side effects. Some have had their promising candidates fail after extensive testing, due to dangerous side effects, but Gilead Sciences Inc. is already raking in billions of dollars from its groundbreaking new drug, Sovaldi.

Merck, based in Whitehouse Station, New Jersey, said it will spend $24.50 in cash for each Idenix share. Idenix closed at $7.23 on Friday, then more than tripled at Monday’s opening bell.

The boards of both companies have approved the deal, which should close in the third quarter.

“Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in (certain) technologies,” Merck’s research head, Dr. Roger Perlmutter, said in a statement.

Three Idenix experimental drugs have reached human testing and one, samatasvir, is in mid-stage testing. It’s in a new drug class called NS5A inhibitors, which disrupt various stages of the virus life cycle. Two other drugs, known as IDX21437 and IDX21459, are in a class called nucleotide prodrugs, which stop the virus from producing genetic material needed to copy itself.

Merck has been testing two drugs together, MK-5172 and MK-8742, that the Food and Drug Administration has deemed a breakthrough therapy. Merck will soon start late-stage testing of the two drugs together and presumably will study them in combinations with the Idenix drugs.

About 4.4 million Americans and an estimated 170 million people worldwide have chronic hepatitis C, the leading cause of liver cancer and, in wealthy countries, the top reason for liver transplants. In the U.S., it kills more than 16,000 people a year.

While most people infected don’t know it because there are no obvious symptoms, a growing number have been identified and started treatment in the last few years as more effective medicines have been approved. That number is expected to grow as the U.S. population ages and patients infected decades ago through intravenous drug use, or from blood transfusions before the early 1990s, are diagnosed.

Merck has been a major player in hepatitis C since acquiring Schering-Plough in 2009. Back then, treatment was limited to twice-a-day pills called ribavirin and self-injections of a long-acting, synthetic form of immune system protein interferon. Treatment often lasted 48 weeks, only about 40 percent of patients were cured, and flu-like symptoms and other side effects of the interferon kept many patients from completing treatment.

In 2011, the FDA approved two drugs in a class called protease inhibitors, Merck’s Victrelis and Incivek from Vertex Pharmaceuticals. Those are taken with ribavirin and interferon, work by blocking an enzyme needed for copying the virus, and boost the cure rate to about 75 percent. But they require patients to take a dozen pills a day, and still endure flu-like side effects.

Last December, the FDA approved Gilead’s once-a-day pill Sovaldi, which cures 80 percent to 90 percent of patients, without the interferon injections and side effects.

Physicians quickly embraced it, and Sovaldi racked up more than $2 billion in sales in its first full quarter on sale, considered the best new drug launch in history. That’s mainly because of Sovaldi’s high price, about $1,000 per pill, or $84,000 for a 12-week treatment course, which continues to draw criticism from patients, insurers and government.

Sovaldi appears poised to dominate the hepatitis C market, greatly outselling Johnson & Johnson’s Olysio, approved about the same time. But there’s plenty of room for Merck and others because Sovaldi can’t be taken by some patients with multiple illnesses or certain hepatitis C subtypes.

In afternoon trading, Idenix shares climbed $16.76 to $23.99. Merck shares slipped 5 cents to $57.80.

Shares of another hepatitis C drug developer, Achillion Pharmaceuticals Inc., now seen as a potential takeover target, climbed 58 percent to $4.55.

 

The Associated Press

The Associated Press

LEAVE A COMMENT

Discussion | No comments

The Daily Republic does not necessarily condone the comments here, nor does it review every post. Read our full policy

.

Solano News

 
 
Teens earn right to perform with symphony

By Amy Maginnis-Honey | From Page: B1 | Gallery

From classical to Queen: Chamber Players are ready

By Amy Maginnis-Honey | From Page: B1 | Gallery

 
Photographer has a passion for color

By Amy Maginnis-Honey | From Page: B1 | Gallery

Solano summit focuses on ways to end poverty

By Kevin W. Green | From Page: A1, 3 Comments | Gallery

 
 
Cadets learn skills for future careers

By Susan Hiland | From Page: A3

 
Sports aircraft company CEO recalls effort to locate in Solano

By Kevin W. Green | From Page: A4 | Gallery

 
‘Souper Bowl’ coming to Solano County

By Bill Hicks | From Page: A4

 
SolTrans announces changes to bus routes

By Kevin W. Green | From Page: A5

Fairfield police log: Jan. 28, 2015

By Susan Hiland | From Page: A12, 2 Comments

 
Suisun City police log: Jan. 28, 2015

By Susan Hiland | From Page: A12

.

US / World

California’s snow survey shows far less snow than last month

By The Associated Press | From Page: A1 | Gallery

 
State to move more than 2,000 inmates

By The Associated Press | From Page: A5

Boy Scouts reaches settlement in sex abuse case

By The Associated Press | From Page: A5

 
Protestors shun sister-city relationship

By The Associated Press | From Page: A5

 
City event criticized for Mexican mafia connection

By The Associated Press | From Page: A5

Tech advances lower chance that driver will die in car crash

By The Associated Press | From Page: A6

 
Police: Family killed man over child custody dispute

By The Associated Press | From Page: A7

Killer says his ideas influenced family suicide

By The Associated Press | From Page: A7

 
NASA astronaut memorial stirs memories for shuttle veteran

By The Associated Press | From Page: A7

‘Anonymized’ credit card data not so anonymous, study shows

By The Associated Press | From Page: A7

 
Poll shows giant gap between what public, scientists think

By The Associated Press | From Page: A7

Fort Hood gunman Hasan says he wants to keep top lawyer

By The Associated Press | From Page: A7

 
Attorney General nominee wins GOP endorsements

By The Associated Press | From Page: A7

 
Simultaneous attacks in Egypt’s Sinai kill 26

By The Associated Press | From Page: A10

Indonesian investigators: Crashed AirAsia flown by co-pilot

By The Associated Press | From Page: A10 | Gallery

 
Gas blast at Mexico children’s hospital, at least 2 dead

By The Associated Press | From Page: A10 | Gallery

Families plead for lives of IS hostages as swap hopes fade

By The Associated Press | From Page: A10

 
Deadly San Francisco blaze spurs look at fire alarms

By T. Burt McNaughton | From Page: A12 | Gallery

 
.

Opinion

Editorial Cartoon: Jan. 30, 2015

By Daily Republic Syndicated Content | From Page: A8

 
 
 
.

Living

Community Calendar: Jan. 30, 2015

By Susan Hiland | From Page: A2

 
Today in History: Jan. 30, 2015

By The Associated Press | From Page: A2

My cousin’s 14-year-old son sleeps in the same bed as his grandma

By Kathy Mitchell and Marcy Sugar | From Page: A9

 
Horoscopes: Jan. 30, 2015

By Holiday Mathis | From Page: A9

.

Entertainment

Week in preview Jan. 30 through Feb. 5, 2015

By Amy Maginnis-Honey | From Page: B1

 
Lil Wayne sues mentor’s record label for $51M, seeking split

By The Associated Press | From Page: B2

Jim Parsons to play God in Broadway’s ‘An Act of God’

By The Associated Press | From Page: B2

 
Lady Gaga, Ariana Grande to pay tribute to Stevie Wonder

By The Associated Press | From Page: B2

Review: A tired gimmick weakens thriller ‘Project Almanac’

By The Associated Press | From Page: B2

 
‘The Thorn Birds’ author Colleen McCullough dies at age 77

By The Associated Press | From Page: B2

Hilary Duff, George Lopez help in search for stolen dog

By The Associated Press | From Page: B2

 
Justin Bieber apologizes for bad behavior in online video

By The Associated Press | From Page: B2

Musician Geezer Butler arrested in Death Valley altercation

By The Associated Press | From Page: B2

 
 
Bernie Mac widow drops malpractice lawsuit against doctor

By The Associated Press | From Page: B3

Entertainment Calendar: Jan. 30, 2015

By Susan Hiland | From Page: B4

 
TVGrid

By Daily Republic Syndicated Content | From Page: B6

Desert stars: Celebs converge on Phoenix for Super Bowl 49

By The Associated Press | From Page: B6

 
.

Sports

Serena aims for 19th major in Aussie final vs. Sharapova

By The Associated Press | From Page: B7

 
Marshawn Lynch talks about why he doesn’t talk to the media

By The Associated Press | From Page: B7

 
Vanden boys pull away from feisty Fairfield 86-66

By Brian Arnold | From Page: B7

Gronkowski and Chancellor make for must-see Super Bowl matchup

By The Associated Press | From Page: B8

 
This date in sports history for Jan. 30, 2015

By The Associated Press | From Page: B9

Signups for Friday, Jan. 30, 2015

By Paul Farmer | From Page: B9

 
.

Business

Chevrolet polishes its mid-size truck

By Ann M. Job | From Page: C1 | Gallery

 
Prospect of Chinese cars in US still remain years away

By The Associated Press | From Page: C2

Senate passes Keystone XL bill, battles loom

By The Associated Press | From Page: B11

 
McDonald’s under siege as new CEO steps in

By The Associated Press | From Page: B11

Obama seeks spending spike for defense, domestic

By The Associated Press | From Page: B11, 1 Comment

 
Who wants a bite of Hershey…jerky?

By The Associated Press | From Page: B11

.

Obituaries

Anthony Neal Hunley

By Nancy Green | From Page: A4

 
Joseph Phillip Raiff

By Nancy Green | From Page: A4, 3 Comments

Frank Z. Perez

By Nancy Green | From Page: A4

 
Dzhon Athanc

By Nancy Green | From Page: A4

Gloria Elizabeth Neal

By Susan Hiland | From Page: A4

 
.

Comics

Blondie

By Daily Republic Syndicated Content | From Page: A8

 
Garfield

By Daily Republic Syndicated Content | From Page: A8

Baby Blues

By Daily Republic Syndicated Content | From Page: A8

 
Wizard of Id

By Daily Republic Syndicated Content | From Page: A8

Beetle Bailey

By Daily Republic Syndicated Content | From Page: A8

 
Pickles

By Daily Republic Syndicated Content | From Page: A8

Baldo

By Daily Republic Syndicated Content | From Page: A8

 
Rose is Rose

By Daily Republic Syndicated Content | From Page: A8

Sally Forth

By Daily Republic Syndicated Content | From Page: A8

 
Peanuts

By Daily Republic Syndicated Content | From Page: A8

Get Fuzzy

By Daily Republic Syndicated Content | From Page: A8

 
Dilbert

By Daily Republic Syndicated Content | From Page: A8

Frank and Ernest

By Daily Republic Syndicated Content | From Page: A8

 
Zits

By Daily Republic Syndicated Content | From Page: A8

B.C.

By Daily Republic Syndicated Content | From Page: A8

 
For Better or Worse

By Daily Republic Syndicated Content | From Page: A8

Cryptoquote

By Daily Republic Syndicated Content | From Page: A9

 
Sudoku

By Daily Republic Syndicated Content | From Page: A9

Word Sleuth

By Daily Republic Syndicated Content | From Page: A9

 
Crossword

By Daily Republic Syndicated Content | From Page: A9

Bridge

By Daily Republic Syndicated Content | From Page: A9